Cellebrite DI (CLBT) - Net Assets
Based on the latest financial reports, Cellebrite DI (CLBT) has net assets worth $484.32 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($938.85 Million) and total liabilities ($454.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CLBT cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $484.32 Million |
| % of Total Assets | 51.59% |
| Annual Growth Rate | 42.09% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 384.86 |
Cellebrite DI - Net Assets Trend (2019–2025)
This chart illustrates how Cellebrite DI's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Cellebrite DI for the complete picture of this company's asset base.
Annual Net Assets for Cellebrite DI (2019–2025)
The table below shows the annual net assets of Cellebrite DI from 2019 to 2025. For live valuation and market cap data, see Cellebrite DI stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $484.32 Million | +44.13% |
| 2024-12-31 | $336.02 Million | +882.17% |
| 2023-12-31 | $34.21 Million | -53.68% |
| 2022-12-31 | $73.86 Million | +200.71% |
| 2021-12-31 | $-73.35 Million | -214.96% |
| 2020-12-31 | $63.80 Million | +8.46% |
| 2019-12-31 | $58.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cellebrite DI's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 365.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $2.22 Million | 0.46% |
| Other Components | $568.64 Million | 117.41% |
| Total Equity | $484.32 Million | 100.00% |
Cellebrite DI Competitors by Market Cap
The table below lists competitors of Cellebrite DI ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Apeloa Pharmaceutical Co Ltd
SHE:000739
|
$3.10 Billion |
|
Ningbo Huaxiang Electronic Co Ltd
SHE:002048
|
$3.10 Billion |
|
Shaanxi Lighte Optoelectronics Material Co. Ltd. A
SHG:688150
|
$3.10 Billion |
|
CCC Intelligent Solutions Holdings Inc.
NASDAQ:CCC
|
$3.10 Billion |
|
China World Trade Center Co Ltd
SHG:600007
|
$3.10 Billion |
|
Bank of Queensland Ltd
AU:BOQ
|
$3.09 Billion |
|
Shurgard Self Storage SA
BR:SHUR
|
$3.09 Billion |
|
Adecco Group AG Class N
SW:ADEN
|
$3.09 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cellebrite DI's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 336,020,000 to 484,318,000, a change of 148,298,000 (44.1%).
- Net income of 78,326,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 133,999.
- Other factors increased equity by 69,838,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $78.33 Million | +16.17% |
| Other Comprehensive Income | $134.00K | +0.03% |
| Other Changes | $69.84 Million | +14.42% |
| Total Change | $- | 44.13% |
Book Value vs Market Value Analysis
This analysis compares Cellebrite DI's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 42.47x to 6.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.31 | $13.35 | x |
| 2020-12-31 | $0.34 | $13.35 | x |
| 2021-12-31 | $-0.45 | $13.35 | x |
| 2022-12-31 | $0.38 | $13.35 | x |
| 2023-12-31 | $0.18 | $13.35 | x |
| 2024-12-31 | $1.60 | $13.35 | x |
| 2025-12-31 | $1.94 | $13.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cellebrite DI utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.17%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.47%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.94x
- Recent ROE (16.17%) is above the historical average (-19.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -3.19% | -1.09% | 0.61x | 4.76x | $-7.76 Million |
| 2020 | 9.06% | 2.97% | 0.53x | 5.71x | $-599.40K |
| 2021 | 0.00% | 28.99% | 0.72x | 0.00x | $78.73 Million |
| 2022 | 163.55% | 44.63% | 0.67x | 5.46x | $113.42 Million |
| 2023 | -237.05% | -24.95% | 0.61x | 15.58x | $-84.52 Million |
| 2024 | -84.22% | -70.54% | 0.58x | 2.06x | $-316.61 Million |
| 2025 | 16.17% | 16.47% | 0.51x | 1.94x | $29.89 Million |
Industry Comparison
This section compares Cellebrite DI's net assets metrics with peer companies in the Software - Infrastructure industry.
Industry Context
- Industry: Software - Infrastructure
- Average net assets among peers: $527,355,826
- Average return on equity (ROE) among peers: -32.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cellebrite DI (CLBT) | $484.32 Million | -3.19% | 0.94x | $3.10 Billion |
| ACI Worldwide Inc (ACIW) | $267.21 Million | 20.72% | 1.00x | $4.34 Billion |
| Aeva Technologies, Inc. Common Stock (AEVA) | $26.91 Million | -95.01% | 0.21x | $821.47 Million |
| Aeva Technologies, Inc. Common Stock (AEVA) | $456.38 Million | -22.24% | 0.05x | $906.22 Million |
| Axe Compute Inc. (AGPU) | $-2.19 Million | 0.00% | 0.00x | $24.93 Million |
| C3 Ai Inc (AI) | $1.06 Billion | -5.25% | 0.13x | $1.26 Billion |
| iLearningEngines, Inc. (AILE) | $264.32 Million | 0.95% | 0.09x | $59.29 Million |
| PowerFleet, Inc. (AIOT) | $13.57 Million | 2.93% | 0.26x | $437.32 Million |
| Airship AI Holdings Inc (AISP) | $-8.36 Million | 0.00% | 0.00x | $83.39 Million |
| AIxCrypto Holdings, Inc. (AIXC) | $2.68 Million | -233.64% | 0.75x | $5.68 Million |
| Akamai Technologies Inc (AKAM) | $3.19 Billion | 9.35% | 0.71x | $15.05 Billion |
About Cellebrite DI
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exp… Read more